StonvexLoading…
StonvexStonvexStonvexCore line items from EMBJ's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $7.58B | $6.39B | $5.27B | $4.54B |
Operating Income | $607.60M | $667.50M | $314.50M | $-110.50M |
Net Income | $359.00M | $354.60M | $164.30M | $-203.50M |
EPS (Diluted) | $0.48 | $0.48 | $0.22 | $-0.25 |
Total Assets | $12.92B | $11.82B | $10.78B | $10.14B |
Total Liabilities | $9.11B | $8.48B | $7.74B | $7.32B |
Cash & Equivalents | $1.95B | $1.56B | $1.63B | $1.82B |
Free Cash Flow OCF − CapEx | $682.80M | $670.80M | $378.30M | $615.10M |
Shares Outstanding | Not available | Not available | Not available | Not available |